Behind the scenes

**MMV Board**

- **Mr Per Wold-Olsen**, Chairman of MMV Board; Former President of Human Health Intercontinental Region, Merck & Co., Inc., Middle East & Africa; Former Member of Merck’s Management Committee; Chairman GN Store Nord A/S, Denmark; Board Member of Gilead Sciences Inc., USA; Board Member of Novo A/S and Exiqon A/S, Denmark
- **Dr Pedro Alonso**, Director, WHO Global Malaria Programme, Switzerland
- **Dr David Brandling-Bennett**, Former Senior Advisor, Malaria, Bill & Melinda Gates Foundation, USA
- **Mr Ray Chambers**, United Nations Secretary-General’s Special Envoy for Health in Agenda 2030 and for Malaria; Co-Founder of Malaria No More, USA
- **Dr Ernest Darkoh**, Chairman & Founding Partner, BroadReach Healthcare, South Africa
- **Prof. Michael Ferguson**, Regius Professor of Life Sciences and Associate Dean for Research Strategy, University of Dundee, Scotland
- **Dr Winston Gutteridge**, Former Chief, Product R&D, Special Programme for Research and Training in Tropical Diseases, WHO, Switzerland
- **Mr Gabriel Jaramillo**, Former General Manager of the Global Fund to Fight AIDS, Tuberculosis and Malaria, Switzerland
- **Dr Robert Newman**, Country Director, US Centers for Disease Control and Prevention, Cambodia; Former Director, WHO Global Malaria Programme
- **Dr David Reddy**, CEO, MMV, Switzerland
- **Ms Wendy Sanhai**, Deloitte Consulting, LLP (Federal Strategy and Operations); Associate Professor (adj), Duke University, School of Medicine; Former: Senior Scientific Advisor, Office of the Commissioner, US Food and Drug Administration; Former: Senior Director, Global Regulatory Affairs, GSK, USA
- **Ambassador Dr Konji Sebati**, CEO, Innovative Pharmaceutical Association of South Africa
- **Mr Gabriel Jaramillo**, Former General Manager of the Global Fund to Fight AIDS, Tuberculosis and Malaria, Switzerland
- **Dr Robert Newman**, Country Director, US Centers for Disease Control and Prevention, Cambodia; Former Director, WHO Global Malaria Programme

**MMV North America Inc. Board**

- **Dr Dennis Schmatz**
  - President of the Board of North America Inc.; Former Vice President, Head of Tsukuba Research Institute, Merck-Banyu Research Laboratories, Japan
- **Dr David Bowen**
  - Independent Advisor, USA
- **Mr Ray Chambers**
  - United Nations Secretary-General’s Special Envoy for Health in Agenda 2030 and for Malaria; Co-Founder of Malaria No More, USA
- **Dr David Reddy**
  - CEO, MMV, Switzerland
- **Ms Wendy Taylor**
  - Director, Center for Accelerating Innovation and Impact at USAID, USA
Expert Scientific Advisory Committee (ESAC)

Dr John Pottage
Co-Chairman MMV
ESAC (Development); Chief Scientific and Medical Officer, ViiV Healthcare, USA

Dr Dennis Schmatz
Co-Chairman MMV
ESAC (Discovery); former Vice-President, Head of Tsukuba Research Institute, Merck-Banyu Research Laboratories, Japan

Dr Aileen Allsop
Former Vice-President for Science Policy, R&D, Astra Zeneca, UK

Prof. Thomas Baillie
Vice Provost, Strategic Science Policy, R&D, Astra Zeneca, UK

Dr Aileen Allsop
Former Vice-President for Science Policy, R&D, Astra Zeneca, UK

Dr Aileen Allsop
Former Vice-President for Science Policy, R&D, Astra Zeneca, UK

Prof. Thomas Baillie
Vice Provost, Strategic Science Policy, R&D, Astra Zeneca, UK

Dr Aileen Allsop
Former Vice-President for Science Policy, R&D, Astra Zeneca, UK

Access & Product Management Advisory Committee (APMAC)

Prof. Christian Lengeler
Chairman of MMV
APMAC; Head, Health Interventions Unit, Swiss Tropical and Public Health Institute, Switzerland

Dr Neena Valecha
Vice-Chairman of MMV
APMAC; Director, National Institute of Malaria Research, India

Ms Valentina Buj
Health Specialist (Malaria Partnerships), UNICEF, USA

Dr Elizabeth Chizema
Director of Disease Control, Surveillance and Research, Ministry of Health, Zambia

Dr Robert Clay
Consultant, Highbury Regulatory Science Limited and Chief Regulatory Officer, Kinapse Ltd., UK

Prof. Umberto D’Alessandro
Theme Leader, Disease Control and Elimination, Medical Research Council, the Gambia

Dr Michael Dunne
Chief Medical Officer, Durata Therapeutics, USA

Prof. Paul Fish
Chair of Medicinal Chemistry, University College London, UK

Prof Daniel Goldberg
Professor and Co-Chief, Division of Infectious Diseases Department of Medicine, Washington University, USA

Prof. Kasturi Haldar
Rev. Julius Nieuwland, CSC Professor of Biological Sciences, Director, Center for Rare and Neglected Diseases, University of Notre Dame, USA

Prof. Tim Hammond
Preadical Safety Consulting Ltd, UK

Prof. Dennis Kyle
Distinguished University Health Professor, College of Public Health, University of South Florida, USA

Dr Marcus Lacerda
Director of Learning and Research at the Fundação de Medicina Tropical Dr Heitor Vieira Dourado, Brazil

Prof. John Lambert
Chief Medical Officer, Global Head Medical Affairs and Consulting, PAREXEL International, UK

Dr Mary Mader
Senior Research Advisor, Discovery Chemistry Research and Technologies, Eli Lilly and Company, USA

Dr Christine Manyando
Head of Public Health Department, Tropical Diseases Research Centre, Zambia

Dr George Mooney
KGM Pharma Consulting LLC, USA

Dr Paul Reider
Pharmaceutical Specialist and Lecturer, Department of Chemistry, Princeton University, USA

Dr David Roberts
Independent Scientific Consultant, UK

Prof. Dennis Shanks
Army Malaria Institute, Australia

Dr Peter Siegl
Director, Siegl Pharma Consulting Ltd, UK

Dr Marcus Lacerda
Director of Learning and Research at the Fundação de Medicina Tropical Dr Heitor Vieira Dourado, Brazil

Dr Michael Witty
Drug Discovery Consultant and Former Vice-President Pfizer R&D, UK

Access & Product Management Advisory Committee (APMAC)

Access & Product Management Advisory Committee (APMAC)

Global Safety Board

Dr Trevor Gibbs
Co-Chairman of MMV
Global Safety Board; Senior Vice-President, Pharmacovigilance & Medical Governance, GlaxoSmithKline, UK

Dr Stephan Duparc
Co-Chairman of MMV
Global Safety Board; Chief Medical Officer, MMV, Switzerland

Sir Colin Dollery
Senior Consultant, GlaxoSmithKline Research and Development, UK

Dr David McGibney
Pharmacetical Research and Development Expert; Consultant Pharmaceutical Physician, UK

Dr Richard Steketee
Science Director, Malaria Control Program and MACEPA, PATH, USA

Prof. Andy Stergachis
Professor of Epidemiology and Global Health, Adjunct Professor of Pharmacy and Health Services, Director of the Global Medicines Program, University of Washington, USA

Dr Brenda Waning
Chief, Global Drug Facility, Stop TB Partnership, Switzerland

Dr David McRibney
Pharmacetical Research and Development Expert; Consultant Pharmaceutical Physician, UK

Prof. Tim Hammond
Preclinical Safety Consulting Ltd, UK

Global Safety Board

Dr Trevor Gibbs
Co-Chairman of MMV
Global Safety Board; Senior Vice-President, Pharmacovigilance & Medical Governance, GlaxoSmithKline, UK

Dr Stephan Duparc
Co-Chairman of MMV
Global Safety Board; Chief Medical Officer, MMV, Switzerland

Sir Colin Dollery
Senior Consultant, GlaxoSmithKline Research and Development, UK

Dr David McGibney
Pharmacetical Research and Development Expert; Consultant Pharmaceutical Physician, UK

Dr Richard Steketee
Science Director, Malaria Control Program and MACEPA, PATH, USA

Prof. Andy Stergachis
Professor of Epidemiology and Global Health, Adjunct Professor of Pharmacy and Health Services, Director of the Global Medicines Program, University of Washington, USA

Dr Brenda Waning
Chief, Global Drug Facility, Stop TB Partnership, Switzerland

Dr David McGibney
Pharmacetical Research and Development Expert; Consultant Pharmaceutical Physician, UK

Prof. Tim Hammond
Preclinical Safety Consulting Ltd, UK
Defeating Malaria Together

George Jagoe  
Executive Vice President,  
Access & Product Management

Elodie Jambert  
Associate Director Asia & Lat Am,  
Access & Product Management

Sandra Johnson  
Director, Outsourcing  
& Relationship Management

Rekha Juncker Kumar  
Legal Assistant

Alexis Kamdjou  
Programme Manager

Franziska Karyabwite  
Executive Vice President,  
Head of Human Resources

Wiweka Kaszubska  
Vice President, Head of Product Development

Elizabeth Kernen  
Administrative Assistant

Benoît Laleu  
Research Scientist, Drug Discovery

Didier Leroy  
Director, Drug Discovery

Peggy Letilly  
Travel Coordinator

Jerry Liwono Yana  
WHO/TDR fellow

Andrea Lucard  
Executive Vice President,  
External Relations

Adrienne MacDonald  
Online Communications Officer

Fiona Macintyre  
Director, Clinical Development

Simona Mag Valigova  
Legal Counsel

Maud Majeres Lugand  
Research & Projects Manager,  
Access & Product Management

Neil McCarthy  
Vice President, Head of External Relations

Jörg Möhrle  
Vice President, Head of Translational Medicine

Alessandra Monaco  
Translational Medicine Scientist

Alice Neequaye  
Quality Officer & Archivist

Alicja Poczatenko  
Senior Legal Counsel

Elizabeth Poll  
Communications Manager

Hanu Ramachandruni  
Senior Director, Technical Product Development

Anya Ramalho  
Executive Vice President,  
Business Development

David Reddy  
Chief Executive Officer

Wendy Redford  
Human Resources Generalist

Véronique Reusse  
Human Resources Recruitment Partner

Emilie Rossignol  
Associate Director, Translational Medicine

Mélanie Rouillier  
Senior Project Coordinator, Discovery

Sahar Sabetnia  
Director, Business Development

Ivana Sirovic Aplon  
External Relations Officer

Andrew Slade  
Director, Translational Medicine

Anouchka Smits Bayala  
Product Development Coordinator

Tareq Sunderji  
Legal Administrative Officer

Yuko Takase  
Finance Officer

André-Marie Tchouatieu  
Associate Director, Access & Product Management

Anna Thomas  
Senior Director, Regulatory Lead

Kim Van der Weijde  
Project Assistant

Helen Weir  
Personal Assistant to the CEO

Timothy Wells  
Chief Scientific Officer

Paul Willis  
Senior Director, Drug Discovery

Antonia Wolff  
Project Coordinator, Translational Medicine
MMV is grateful for the support of the following institutional donors in 2016:

[Images of institutional logos]

MMV is also grateful for the support received from private individuals.